MRNA Gross Margin
Percentage of revenue retained after cost of goods sold.
Gross Margin
Latest: 35.9% (2026Q2)
| Period | Value |
|---|---|
| 2023Q1 | 57.5% |
| 2023Q2 | -112.5% |
| 2023Q3 | -22.4% |
| 2023Q4 | 67.0% |
| 2024Q1 | 42.5% |
| 2024Q2 | 52.3% |
| 2024Q3 | 72.4% |
| 2024Q4 | 23.5% |
| 2025Q1 | 16.7% |
| 2025Q2 | 16.2% |
| 2025Q3 | 79.6% |
| 2025Q4 | 33.3% |
| 2026Q1 | -145.5% |
| 2026Q2 | 35.9% |
Other MRNA Charts
More quarter-by-quarter fundamentals for Moderna, Inc.
1 / 10
Revenue
EPS
Free Cash Flow
FCF Margin
P/E Ratio
Cumulative FCF
Shares Outstanding
Total Assets
Total Debt
Rule of 40
Healthcare Comparison
1 / 3
Gross Margin
Gross Margin
Gross Margin
Latest Gross Margin: 35.9% (2026Q2); +19.7 pp YoY.
Across the 14 quarters from 2023Q1 to 2026Q2, Gross Margin ranged from -145.5% in 2026Q1 to 79.6% in 2025Q3.